research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
Search
for
Sort by
Research
840-870 / 1000+ results research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research Announcements
Various dermatology events and meetings were announced for 1998.
research Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
research Therapeutic Evaluation of Spironolactone and Finasteride in the Treatment of Acne Vulgaris
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo
3D imaging effectively tracks skin changes in vitiligo treatment.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
research PD05-05 SINGLE CENTRE EXPERIENCE OF CHELATING AGENTS IN CYSTINURIA
Both penicillamine and tiopronin have significant side effects, but trying the alternative drug can be beneficial if the first is not tolerated.
research Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
research Serum irisin level in patients with acne vulgaris
Patients with acne vulgaris have lower serum irisin levels.
research Successful Treatment of Canities Subita with Baricitinib
Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Comparative Evaluation of Superficial Cryotherapy vs Intralesional Triamcinolone in Alopecia Areata at a Tertiary Care Center: A Dermoscopic and Clinical Study in Middle-aged Adults
Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.
research Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
research Experience in treating multifocal alopecia areata in a child with Jak kinase inhibitors
JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Topical tofacitinib in treatment of alopecia areata
Topical tofacitinib shows promise as a future treatment for alopecia areata.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research High-coverage genome of the Tyrolean Iceman reveals unusually high Anatolian farmer ancestry
The Tyrolean Iceman had mostly Anatolian farmer ancestry and traits like darker skin and a risk for certain health issues.
research Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.